Midterm Psychopharm
(2025) Actual Exam
Questions and Answers A+
Graded
Typical,.antipsychotics,.(conventional),.(FGA)
Treats,.positive,.(+),.symptoms,.only,.appropriate,.for,.the,.acute,
.and,.chronic
management,.of,.schizophrenia,.and,.psychosis.
Non-
selectively,.blocks,.dopamine,.D2,.receptors,,.specifically,.in,. mes
olimbic,.pathway;
also,.blocks,.Ach,.(Muscarinic),,.histamine,,.N
E,.Five,.main,.SE,.of,.FGAs
., . Sedation
., . Postural,.Hypotension
., . Lower,.seizure,.threshold
., . Anticholinergic,.side,.effects
., . Photosensitive
Haloperidol-High-Appropriate, . for, . acute,, . severe, . agitation, . and, . aggression-Butyrophenones
., . Initial,. oral,.dose,.1-15mg/day,.(can,.give,.once,.daily,.or,.divide;
., . Usual,.dose,.1-40mg/day,.(orally);
., . Max,.dose,.100mg/day
., . Tablets,.0.5,,.1,,.2,,.5,,.10,,.20mg;,.Concentrate,.2mg/ml;,.Injection,.5mg/ml
., . Half-life,.13-38
., . Higher,.risk,.for,.EPS,.and,.TD
., . Avoid,.in,.older,.adults,.due,.to,.increased,.risk,.of,.cerebrovascular,.accident,.(C
VA),, . cognitive
decline,,.and,. death,. in,. persons,. with,. dementia,. and,. with,.dementia-related,. psychosis.
Fluphenazine-Medium-Psychotic ,.D/Os
., . Initial,.oral,.dose,.0.5-10mg/day,.divided,.doses;
., . Usual,.dose,.1-20mg,.day;
., . Max,.dose40mg/day
., . Tablet,.1,,.2.5,,.5,,.10mg;,.Elixer,.2.5mg/ml;,.Concentrate,.5mg/ml
., . Half-life,.15,.hours
Thiothixene-Medium
., . Initial,.dose,.5-10mg/day;
., . Usual,.dose,.15-30mg/day;
., . Max,.dose,.60mg/day,. divided
., . Capsules,.2,,.5,,.10mg
., . Half-life,.3.4-34,.hours
Thioridazine-Low-2nd,.line,.due,. to,. QTc,. issues
., . Initial,. dose,. 50-100mg/3xday/increase,. gradually;
., . Usual,.dose,.200-800mg,.divided;
about:blank 1/34
, ., . Max,.dose,.800mg/day
., . Tablets,.10,,.15,,.25,,.50,,.100mg
., . Metabolized,.by,.CYP450,.2D6
Chlorpromazine-Low-2nd,. line, . due, . to, . QTc, . issues, . -schizophrenia-DA,. 2, . antagonist
., . Usual,.dose,. 200-800mg,.divided;,. maximum,.800mg/day
., . Psychosis-
increase,.dose,.until,.symptoms,.are,.controlled;,.after,.2,.weeks,.reduce,.to,.lowest, . effective
,.dose
., . Can,.improve,.in,.one,.week,.but,. may,.take,.several,.weeks,.for,.full,.effect,.on,.behavior
about:blank 2/34
, ., . Tablet,.10,,.25,,.50,,.100,,.200mg
., . Half-Life,.8-33,.hours
., . Phenothyazine
., . SXS-
Dry,.mouth,,.pupil,.dilation,,.blurred,.vision,,.cog,.impair,,.constipation,,.urinary, . reten
tion,,.tachycardia
Mesoridazine-Low-off, . market, . due, . to, . dangerous, . side, . effects,, . including, . irregular, . heartbeat
and
QT,.prolongation.
*Low,.potency,. meds,. require,.higher,.doses,. to,.achieve,.efficacy
*Low,.potency,.meds,.have,.more,.anticholinergic,,.antihistaminic,,.and,.a,.1,.properties,.resul
ting,.in, . more,.sedation,.than,.higher,.potency,.meds.
*High,.risk,. for,. developing,. hyperprolactinemia,.and,. EPS,. (negative,. symptoms,.aren’t,. affected,. by
FGAs,.only,.positive,. symptoms)
Neurolepsis,.is,.a,.term,.to,.describe,.antipsychotic,.medication,.effects,.on,.psychotic,.clients
,,.with, . respect,.to,.cognition,.and,.behavior.,.Newer,.medications,.(SGA),.do,.not,.necessarily,
.have,.these,.same, . effects.
Neurolepsis,. syndrome,. has,.three,.major,.features.,.Examine,.the,.image,.below,.to,.learn
more,.about
the,.PEA,.acronym.
., . Psychomotor, . slowing, . -
, . extreme, . form, . of, . slowness, . or, . absence, . of, . motor, . movement, . (nigrostriatal,.pathway
)
., . Emotional, . quieting, . -, . worsening, . of, . negative, . and, . cognitive, . symptoms, . (mesocortical
pathways)
.,. Affective,.indifference,.-
,.worsening,.of,.affective,.symptoms,.(mesocortical,.pathway), . Atypical,.antipsyc
hotics,.(SGA),.Developed,.to,.treat,.both,.positive,.(+),.and,.(-
),.negative
symptoms
., . SGAs,.are,.considered,.serotonin-
dopamine,.antagonists,,.as,.they,.maintain,.D2,.antagonism, . but,.also,.have,.simultaneo
us,.serotonin,.5HT2A,.antagonism
., . Lower,.affinity,. for,.D2,.and,.higher,.affinity,.for,.5HT
., . Effective,. for,.treatment-resistant,.clients
., . Does,.not,.increase,. prolactin,.levels
., . Treats,.positive,.and,.negative,.symptoms
., . Lower,.risk,.of,.EPS
Olanzapine-Schizophrenia-, . age, . 13, . and, . older
., . Serotonin-Dopamine,.antagonist-
reducing,.positive,.sxs;,.Antagonist,.actions,.at,.the,.5HT2C, . receptor,.may,.contribute,.to,.ef
ficacy,.for,.cognitive,.and,.affective,.sxs
., . *More,.weight,. gain,.and,. metabolic,.effects
., . *High,. metabolic,.risk
., . Highest,.risk,.for,.weight,.gain,,.blood,.dyscrasias,,.QT,.prolongation,,.cardiovascular,.dise
ase,, . cerebrovascular,.effects,,.hyperglycemia,,.and,.*hyperprolactinemia
., . Most,.commonly,. used,. in,.pregnant,. women,.with,. least,.risk,. for,.congenital,. harm
., . Half-life,.21-54,. hours
., . Substrate,. for,.CYP450,.1A2,.and,.2D6
., . Usual,.dose,.1-20mg/d
., . Initial,.dose,.5-10mg/d,. increase,.by,.5mg/day,.once,.a,.week,.until,.desired,.efficacy
about:blank 3/34
, This,.is,.a,.preview
about:blank 4/34
(2025) Actual Exam
Questions and Answers A+
Graded
Typical,.antipsychotics,.(conventional),.(FGA)
Treats,.positive,.(+),.symptoms,.only,.appropriate,.for,.the,.acute,
.and,.chronic
management,.of,.schizophrenia,.and,.psychosis.
Non-
selectively,.blocks,.dopamine,.D2,.receptors,,.specifically,.in,. mes
olimbic,.pathway;
also,.blocks,.Ach,.(Muscarinic),,.histamine,,.N
E,.Five,.main,.SE,.of,.FGAs
., . Sedation
., . Postural,.Hypotension
., . Lower,.seizure,.threshold
., . Anticholinergic,.side,.effects
., . Photosensitive
Haloperidol-High-Appropriate, . for, . acute,, . severe, . agitation, . and, . aggression-Butyrophenones
., . Initial,. oral,.dose,.1-15mg/day,.(can,.give,.once,.daily,.or,.divide;
., . Usual,.dose,.1-40mg/day,.(orally);
., . Max,.dose,.100mg/day
., . Tablets,.0.5,,.1,,.2,,.5,,.10,,.20mg;,.Concentrate,.2mg/ml;,.Injection,.5mg/ml
., . Half-life,.13-38
., . Higher,.risk,.for,.EPS,.and,.TD
., . Avoid,.in,.older,.adults,.due,.to,.increased,.risk,.of,.cerebrovascular,.accident,.(C
VA),, . cognitive
decline,,.and,. death,. in,. persons,. with,. dementia,. and,. with,.dementia-related,. psychosis.
Fluphenazine-Medium-Psychotic ,.D/Os
., . Initial,.oral,.dose,.0.5-10mg/day,.divided,.doses;
., . Usual,.dose,.1-20mg,.day;
., . Max,.dose40mg/day
., . Tablet,.1,,.2.5,,.5,,.10mg;,.Elixer,.2.5mg/ml;,.Concentrate,.5mg/ml
., . Half-life,.15,.hours
Thiothixene-Medium
., . Initial,.dose,.5-10mg/day;
., . Usual,.dose,.15-30mg/day;
., . Max,.dose,.60mg/day,. divided
., . Capsules,.2,,.5,,.10mg
., . Half-life,.3.4-34,.hours
Thioridazine-Low-2nd,.line,.due,. to,. QTc,. issues
., . Initial,. dose,. 50-100mg/3xday/increase,. gradually;
., . Usual,.dose,.200-800mg,.divided;
about:blank 1/34
, ., . Max,.dose,.800mg/day
., . Tablets,.10,,.15,,.25,,.50,,.100mg
., . Metabolized,.by,.CYP450,.2D6
Chlorpromazine-Low-2nd,. line, . due, . to, . QTc, . issues, . -schizophrenia-DA,. 2, . antagonist
., . Usual,.dose,. 200-800mg,.divided;,. maximum,.800mg/day
., . Psychosis-
increase,.dose,.until,.symptoms,.are,.controlled;,.after,.2,.weeks,.reduce,.to,.lowest, . effective
,.dose
., . Can,.improve,.in,.one,.week,.but,. may,.take,.several,.weeks,.for,.full,.effect,.on,.behavior
about:blank 2/34
, ., . Tablet,.10,,.25,,.50,,.100,,.200mg
., . Half-Life,.8-33,.hours
., . Phenothyazine
., . SXS-
Dry,.mouth,,.pupil,.dilation,,.blurred,.vision,,.cog,.impair,,.constipation,,.urinary, . reten
tion,,.tachycardia
Mesoridazine-Low-off, . market, . due, . to, . dangerous, . side, . effects,, . including, . irregular, . heartbeat
and
QT,.prolongation.
*Low,.potency,. meds,. require,.higher,.doses,. to,.achieve,.efficacy
*Low,.potency,.meds,.have,.more,.anticholinergic,,.antihistaminic,,.and,.a,.1,.properties,.resul
ting,.in, . more,.sedation,.than,.higher,.potency,.meds.
*High,.risk,. for,. developing,. hyperprolactinemia,.and,. EPS,. (negative,. symptoms,.aren’t,. affected,. by
FGAs,.only,.positive,. symptoms)
Neurolepsis,.is,.a,.term,.to,.describe,.antipsychotic,.medication,.effects,.on,.psychotic,.clients
,,.with, . respect,.to,.cognition,.and,.behavior.,.Newer,.medications,.(SGA),.do,.not,.necessarily,
.have,.these,.same, . effects.
Neurolepsis,. syndrome,. has,.three,.major,.features.,.Examine,.the,.image,.below,.to,.learn
more,.about
the,.PEA,.acronym.
., . Psychomotor, . slowing, . -
, . extreme, . form, . of, . slowness, . or, . absence, . of, . motor, . movement, . (nigrostriatal,.pathway
)
., . Emotional, . quieting, . -, . worsening, . of, . negative, . and, . cognitive, . symptoms, . (mesocortical
pathways)
.,. Affective,.indifference,.-
,.worsening,.of,.affective,.symptoms,.(mesocortical,.pathway), . Atypical,.antipsyc
hotics,.(SGA),.Developed,.to,.treat,.both,.positive,.(+),.and,.(-
),.negative
symptoms
., . SGAs,.are,.considered,.serotonin-
dopamine,.antagonists,,.as,.they,.maintain,.D2,.antagonism, . but,.also,.have,.simultaneo
us,.serotonin,.5HT2A,.antagonism
., . Lower,.affinity,. for,.D2,.and,.higher,.affinity,.for,.5HT
., . Effective,. for,.treatment-resistant,.clients
., . Does,.not,.increase,. prolactin,.levels
., . Treats,.positive,.and,.negative,.symptoms
., . Lower,.risk,.of,.EPS
Olanzapine-Schizophrenia-, . age, . 13, . and, . older
., . Serotonin-Dopamine,.antagonist-
reducing,.positive,.sxs;,.Antagonist,.actions,.at,.the,.5HT2C, . receptor,.may,.contribute,.to,.ef
ficacy,.for,.cognitive,.and,.affective,.sxs
., . *More,.weight,. gain,.and,. metabolic,.effects
., . *High,. metabolic,.risk
., . Highest,.risk,.for,.weight,.gain,,.blood,.dyscrasias,,.QT,.prolongation,,.cardiovascular,.dise
ase,, . cerebrovascular,.effects,,.hyperglycemia,,.and,.*hyperprolactinemia
., . Most,.commonly,. used,. in,.pregnant,. women,.with,. least,.risk,. for,.congenital,. harm
., . Half-life,.21-54,. hours
., . Substrate,. for,.CYP450,.1A2,.and,.2D6
., . Usual,.dose,.1-20mg/d
., . Initial,.dose,.5-10mg/d,. increase,.by,.5mg/day,.once,.a,.week,.until,.desired,.efficacy
about:blank 3/34
, This,.is,.a,.preview
about:blank 4/34
